

4 September 2009

## Proposal for lansoprazole (Solox)

PHARMAC is seeking feedback on a proposal for lansoprazole (Solox) through a provisional agreement with Douglas Pharmaceuticals. Lansoprazole is a proton-pump inhibitor used for various conditions including reflux oesophagitis, duodenal and gastric ulcers.

If implemented, the proposal would result in a subsidy and price reduction for Solox in return for subsidy and delisting protection.

### Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 5 pm on **Friday 18 September 2009** to:

Mike Bignall  
 Therapeutic Group Manager  
 PHARMAC

Email: [mike.bignall@pharmac.govt.nz](mailto:mike.bignall@pharmac.govt.nz)  
 Fax: 04 460 4995  
 Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

### Details of the proposal

- The listing of Solox would be amended in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 November 2009 as follows:

Chemical	Form and Strength	Brand	Pack size	Current price and subsidy	Proposed price and subsidy
Lansoprazole	Cap 15 mg	Solox	28	\$4.30	\$3.50
	Cap 30 mg		28	\$8.59	\$4.65

*Prices are ex-manufacturer, excluding GST*

- Solox would have subsidy and delisting protection until 31 October 2012.